First-Line Ibrutinib Confirmed for CLL

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2018-166
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter

Clinical Cancer Research
Cancer ResearchOncology
2016English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Complex Case of Ibrutinib Treatment for a CLL Patient on Haemodialysis

British Journal of Haematology
Hematology
2017English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Going Through Changes: Surface IgM Levels During CLL Therapy With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2019English

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Ptbp1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy